REGENT PACIFIC GROUP LIMITED
勵晶太平洋集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 575)

Voluntary Announcement
Launch of Accrua™ – Deep Longevity's Consumer Digital Health Platform in the United States

This announcement is made by the board (the "**Board**") of directors (the "**Director(s)**") of Regent Pacific Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company (the "**Shareholders**") and potential investors informed of the latest business developments of the Group.

Launch of Accrua by Deep Longevity

The Board is delighted to announce that Deep Longevity, Inc, a wholly owned subsidiary of the Company, and its subsidiary (collectively "**Deep Longevity**"), will launch Accrua™ ("**Accrua**"), its consumer digital health and telehealth platform, in the United States (the "**US**") in October 2026 (the "**Launch**"). Accrua will be available to consumers across all 50 US states from the date of the Launch.

The Launch represents the culmination of Deep Longevity's strategy, as set out in the Company's 2026 interim results announcement and 2026 interim report dated 25 August 2026, of scaling in the US market through a direct-to-consumer ("**D2C**") digital telehealth offering. The Board regards Accrua as a potentially transformational development for the Group and a significant new source of future revenue, complementing Deep Longevity's existing business-to-business ("**B2B**") model.

About Accrua

Accrua provides medical care online that is simple, direct and led by licensed US clinicians. At the heart of the platform is Deep Longevity's proprietary, AI-generated BloodAge report, which uses a routine blood test to indicate whether a consumer is a "faster ager" – someone whose biological age is advancing more quickly than their chronological age.

Following a clinician consultation, Accrua offers doctor-guided access to a range of treatment categories, including medications for weight loss (such as glucagon-like peptide-1 ("**GLP-1**") therapies), peptides, women's health (such as hormone replacement therapy) and men's health (such as testosterone therapies). In each case, the initial treatment plan and subsequent adjustments are personalised by a licensed clinician and anchored to the user's BloodAge report, rather than to self-reported symptoms or a single biomarker. Users have their BloodAge re-measured on a quarterly basis, so that both the users and their clinician can track the effect of treatment against an objective, science-based measure of biological ageing, rather than relying on symptoms or weight alone.

Accrua is positioned around a simple proposition – “You know your age. Your blood knows better.” – offering quarterly biological age measurement, clinician-guided treatment protocols and compounded therapies as an integrated longevity care programme, backed by peer-reviewed science. The platform’s initial launch categories include weight loss, women’s health and men’s health, with further categories planned.

Accrua extends access to Deep Longevity’s deep learning ageing clock technology and SenoClock® platform directly to consumers for the first time, alongside Deep Longevity’s existing work with clinics, hospitals, laboratories and insurance companies.

A Differentiated, Science-led Platform

The Board believes Accrua is differentiated from other US digital telehealth platforms by the independent, peer-reviewed clinical research underpinning Deep Longevity’s technology. Deep Longevity’s BloodAge model was the subject of a peer-reviewed study by Goshen et al. (Aging and Disease, 2026), which followed approximately 2,600 adults over an average of 9.2 years and found that each additional year of gap between biological and chronological age was independently associated with a 15% increase in mortality risk and a 6% increase in hospitalisation risk, after adjusting for age, sex, body mass index (“**BMI**”), smoking and hypertension.

Deep Longevity’s technology has also received notable external recognition, most recently being named Runner-Up in the Nestlé VITAL Smart Aging Global Challenge, a global innovation competition that drew entries from 150 companies worldwide.

A Large and Fast-growing Market

Accrua enters a US consumer digital health market in which substantial revenues have been achieved by platforms addressing adjacent health and wellness categories. By way of illustration, MEDVi, LLC, a US digital telehealth platform focused on GLP-1 weight-loss and related therapies, was reported by The New York Times (2 April 2026) to have generated over US$400 million in revenue in 2025, its first full year of operation, and to be on track for a 2026 revenue run-rate of approximately US$1.8 billion (Forbes, 2 April 2026, citing The New York Times). Accrua addresses a similar range of product categories. While no assurance can be given that Accrua will achieve comparable results, the Board believes these figures illustrate the scale of consumer demand and the revenue potential of the market that Accrua is designed to address.

Capital-efficient, Scalable Business Model

Accrua has been built on a capital-efficient model. Clinical delivery will be provided through established US telehealth infrastructure partners via a network of independent, licensed physicians and pharmacy and compounding partners, covering clinician consultations, prescriptions, pharmacy fulfilment and delivery, patient intake and patient portal, electronic health records, billing and payment processing, secure video consultations and patient communications, in all 50 US states. This allows Deep Longevity to scale nationally from the date of the Launch without owning clinical infrastructure or carrying drug inventory directly.

Revenues are expected to be largely subscription-based and recurring in nature. The Launch will be supported by targeted digital marketing campaigns, initially focused on a selected group of US states, with the aim of optimising customer acquisition before scaling further.

Regulatory and Compliance Framework

All treatments available through Accrua are prescribed by licensed US clinicians following an individual consultation through our US infrastructure partners and the platform operates on infrastructure that is compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Accrua will be LegitScript certified ahead of the Launch.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, each of the two service providers and their ultimate beneficial owner(s) are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

Reasons for and Benefits of the Strategic Development

The Board is highly enthusiastic about the Launch. Accrua brings together Deep Longevity's world-class ageing clock technology, independent peer-reviewed science and an established, scalable telehealth delivery model to address one of the largest and fastest-growing categories in US consumer healthcare. The Board believes Accrua has the potential to become a significant driver of revenue growth for the Group and to create meaningful long-term value for Shareholders, and looks forward to updating Shareholders on Accrua's progress following the Launch.

Mr. Jamie Gibson, Executive Director and Chief Executive Officer of the Company, commented: *"The launch of Accrua is a landmark moment for Deep Longevity and for the Group. For the first time, consumers across the US will be able to access our BloodAge science directly, with personalised care from licensed clinicians. We believe anchoring treatment to biological age – rather than to symptoms alone – is a genuinely new proposition in a market that has already demonstrated exceptional consumer demand, and we are excited about the opportunity ahead."*

Cautionary Statement

Shareholders and potential investors should note that Accrua is a newly launched business and that the revenues to be generated from it, if any, are uncertain and will depend on a number of factors, including consumer demand, customer acquisition costs, competition, the performance of third party clinical and fulfilment partners, and the regulatory environment for digital telehealth and compounded medications in the US. The market information relating to other platforms referred to in this announcement is derived from published third party sources and is provided for illustrative purposes only; the commercialisation progress and market benefits of Accrua remain uncertain and may not generate anticipated returns for the Group and it does not constitute a forecast of Accrua's performance. As at the date of this announcement, the aforementioned development is not expected to have any material impact on the Group's financial position or operating results for the financial year ending 31 December 2026. The Company will issue separate announcement(s) as and when appropriate regarding any material progress in the aforementioned development, in accordance with the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the shares of the Company.

By Order of the Board
Regent Pacific Group Limited
Jamie Gibson
Executive Director

Hong Kong, 28 September 2026

As at the date of this announcement, the Board comprises six Directors**:**

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliffe

Independent Non-Executive Directors:
Mark Searle
Adrian Chan
Ihsan Al Chalabi